A phase 1 first-in-human study of the anti-LAG-3 antibody MK4280 (favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer.

Elena Garralda(Memorial Sloan Kettering Cancer Center), Gerald S. Falchook(The University of Texas MD Anderson Cancer Center), Martin Wermke(National Center for Tumor Diseases), Marya Chaney(Merck & Co., Inc., Rahway, NJ, USA (United States)), Yanyan Lou(WinnMed), Jane Healy(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ravit Geva(Tel Aviv Sourasky Medical Center), Sujata Jha(Merck & Co., Inc., Rahway, NJ, USA (United States)), Seock‐Ah Im(Seoul National University), Amita Patnaik(South Texas Accelerated Research Therapeutics), Talia Golan(Sheba Medical Center), Nehal J. Lakhani(South Texas Accelerated Research Therapeutics), John Palcza(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ammar Sukari(The Barbara Ann Karmanos Cancer Institute)
Journal of Clinical Oncology
May 20, 2021
10.1200/jco.2021.39.15_suppl.3584
Cited by 46

Related Papers

Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
|The Lancet|2020|1.8k